Riccardo Canevari reported 1 trade in Radiopharm Theranostics Limited shares (Appendix 3Y, ASX)

Appendix 3Y

*Rule 3.19A.2*

Change of Director’s Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given
to ASX become ASX’s property and may be made public.*

Introduced 30/9/2001.

Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of
section 205G of the Corporations Act.

Name of Director:	Bruce Goodwin
Date of Last Notice:	22 September 2026

Part 1 - Change of director’s relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a
director” should be disclosed in this part.

Direct or Indirect InterestIndirectNature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.Sundial Management Pty Limited of which of which Mr Goodwin is a Director and Shareholder.Date of change16 October 2026No. of securities held prior to changeSharesOptionsIndirect2,777,7782,777,778ClassListed OptionsNumber acquiredNilNumber disposed1,111,111 Listed Options, EXP 31 Jul 29, EX $0.018Value/Consideration Note: If consideration is non-cash, provide details and estimated valuationNilNo. of securities held after changeSharesOptionsIndirect2,777,7781,666,667

• See chapter 19 for defined terms.

---

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-backCancellation of Listed options

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a
director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

---

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

---

Appendix 3Y

*Rule 3.19A.2*

Change of Director’s Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given
to ASX become ASX’s property and may be made public.*

Introduced 30/9/2001.

Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of
section 205G of the Corporations Act.

Name of Director:	Ian Turner
Date of Last Notice:	22 September 2026

Part 1 - Change of director’s relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a
director” should be disclosed in this part.

Direct or Indirect InterestDirect and indirectNature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.Superannuation fundDate of change16 October 2026No. of securities held prior to changeSharesOptionsDirect3,752,81723,179,148Indirect9,010,2531,625,978Total12,763,07024,805,126ClassListed OptionsNumber acquiredNilNumber disposed1,111,111 Listed Options, EXP 31 Jul 29, EX $0.018Value/Consideration Note: If consideration is non-cash, provide details and estimated valuationNil

---

No. of securities held after changeSharesOptionsDirect3,752,81722,068,037Indirect9,010,2531,625,978Total12,763,07023,694,015Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-backCancellation of Listed options

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a
director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

---

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

---

Appendix 3Y

*Rule 3.19A.2*

Change of Director’s Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given
to ASX become ASX’s property and may be made public.*

Introduced 30/9/2001.

Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of
section 205G of the Corporations Act.

Name of Director:	Paul Hopper
Date of Last Notice:	22 September 2026

Part 1 - Change of director’s relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a
director” should be disclosed in this part.

Direct or Indirect InterestDirectNature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.N/ADate of change16 October 2026No. of securities held prior to changeSharesOptionsDirect53,900,00026,142,000Indirect96,599,20611,795,296Total150,499,20637,937,296ClassListed OptionsNumber acquiredNilNumber disposed1,111,111 Listed Options, EXP 31 Jul 29, EX $0.018Value/Consideration Note: If consideration is non-cash, provide details and estimated valuationNil

---

No. of securities held after changeSharesOptionsDirect53,900,00026,142,000Indirect96,599,20610,684,185Total150,499,20636,826,185Nature of changeExample:on-market trade, off-market trade, exercise of options, issueof securities under dividend reinvestment plan, participationin buy-backCancellation of Listed options.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a
director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

---

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

---

Appendix 3Y

*Rule 3.19A.2*

Change of Director’s Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given
to ASX become ASX’s property and may be made public.*

Introduced 30/9/2001.

Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of
section 205G of the Corporations Act.

Name of Director:	Riccardo Canevari
Date of Last Notice:	1 October 2026

Part 1 - Change of director’s relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a
director” should be disclosed in this part.

Direct or Indirect InterestDirectNature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.N/ADate of change16 October 2026No. of securities held prior to changeSharesOptionsDirect23,918,875163,301,188Indirect2,650,000-Total26,568,875163,301,188ClassListed OptionsNumber acquiredNilNumber disposed1,555,556 Listed Options, EXP 31 Jul 29, EX $0.018Value/Consideration Note: If consideration is non-cash, provide details and estimated valuationNil

---

No. of securities held after changeSharesOptionsDirect23,918,875161,745,632Indirect2,650,000-Total26,568,875161,745,632Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-backCancellation of Listed options.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a
director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

---

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.